Xanthohumol Blood Glucose Randomized Trial: What the Evidence Says

Quick Answer

Xanthohumol Blood Glucose Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Specifically, XN modified bile acid profiles and reduced microbiota-derived secondary bile acids in an enterotype-dependent manner in healthy adults. [Bradley Ryan (2026); evidence level 2]
• XN may also be a novel candidate therapeutic in IBD due to its effects on cardiometabolic inflammation, which may be caused by increased gut barrier permeability and resultant endotoxin/lipopolysaccharide-induced increases in proprotein convertase subtilisin/kexin type 9 (PCSK-9). [Bradley Ryan (2026); evidence level 2]
• C k t t VCO VO 1 2 3 4 5 6 7 8 9 10 Xanthohumol is a prenylated chalcone that can be found at low concentrations in hops, which is why intake of xanthohumol via food is only possible in small quantities. [Brehmer‐Henkel Sara (2026); evidence level 2]
• Smaller quantities of mixed metabolites containing sulfates and glucuronides as well as double glucuronide conjugates of xanthohumol and derived prenylated chalcones and flavonoids were also found. [Brehmer‐Henkel Sara (2026); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For xanthohumol blood glucose randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Bradley Ryan (2026). Safety and Tolerability of Xanthohumol in Adults With Crohn's Disease: Results of a Triple‐Masked, Randomized, Placebo‐Controlled Phase 2 Trial. DOI: 10.1002/mnfr.70438. PMCID: PMC12989708. PMID: 41834265. License: https://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/ This is an open access.... https://pmc.ncbi.nlm.nih.gov/articles/PMC12989708/
• Brehmer‐Henkel Sara (2026). The Bioavailability of Xanthohumol in Humans and the Influence of Formulation and Dose: Randomized Controlled Trial Data. DOI: 10.1002/mnfr.70413. PMCID: PMC12925386. PMID: 41723719. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12925386/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.